ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 102 filers reported holding ASCENDIS PHARMA A/S in Q2 2018. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $48,959,306 | -9.8% | 417,172 | +3.3% | 3.76% | +8.4% |
| Q4 2021 | $54,306,801 | -23.5% | 403,678 | -9.3% | 3.47% | -29.6% |
| Q3 2021 | $70,960,906 | +123.1% | 445,203 | +84.1% | 4.93% | +132.4% |
| Q2 2021 | $31,805,370 | -20.9% | 241,774 | -22.5% | 2.12% | -29.8% |
| Q1 2021 | $40,193,419 | +28.8% | 311,867 | +66.7% | 3.02% | -17.4% |
| Q4 2020 | $31,195,032 | +25.6% | 187,043 | +16.2% | 3.66% | -33.7% |
| Q3 2020 | $24,846,137 | -23.8% | 161,004 | -26.9% | 5.52% | +23.5% |
| Q2 2020 | $32,588,878 | +5.0% | 220,344 | -20.0% | 4.47% | -42.1% |
| Q1 2020 | $31,023,379 | +9.9% | 275,494 | +35.8% | 7.71% | +54.7% |
| Q4 2019 | $28,226,613 | +24.0% | 202,894 | -14.2% | 4.98% | -29.4% |
| Q3 2019 | $22,769,277 | +45.0% | 236,392 | +73.3% | 7.06% | +60.6% |
| Q2 2019 | $15,706,115 | +29.2% | 136,397 | +32.0% | 4.40% | +24.0% |
| Q1 2019 | $12,157,939 | +1172.2% | 103,296 | +577.2% | 3.55% | +586.1% |
| Q4 2018 | $955,663 | -29.2% | 15,254 | -19.9% | 0.52% | -12.8% |
| Q3 2018 | $1,350,166 | -32.5% | 19,054 | -36.6% | 0.59% | -35.1% |
| Q2 2018 | $1,999,192 | +27.1% | 30,054 | +24.9% | 0.91% | +25.0% |
| Q1 2018 | $1,573,132 | +224.1% | 24,054 | +98.5% | 0.73% | +162.0% |
| Q4 2017 | $485,447 | – | 12,118 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |